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Abstract 
Our previous studies indicated that p16 suppresses breast cancer angiogenesis and metastasis, 
and downregulates VEGF gene expression by neutralizing the transactivation of the VEGF 
transcriptional factor HIF-1α. Hypoxia stimulates tumor malignant progression and induces 
HIF-1α. Because p16 neutralizes effect of HIF-1α and attenuates tumor metastatic progres-
sion, we intended to investigate whether p16 directly affects one or more aspects of the 
malignant process such as adhesion and migration of breast cancer cells. To approach this aim, 
MDA-MB-231 and other breast cancer cells stably transfected with Tet-on inducible p16 were 
used to study the p16 effect on growth, adhesion and migration of the cancer cells. We found 
that p16 inhibits breast cancer cell proliferation and migration, but has no apparent effect on 
cell adhesion. Importantly, p16 inhibits hypoxia-induced cell migration in breast cancer in 
parallel with its inhibition of HIF-1α transactivation activity. This study suggests that p16’s 
ability to suppress tumor metastasis may be partially resulted from p16’s inhibition on cell 
migration, in addition to its known functions on inhibition of cell proliferation, angiogenesis 
and induction of apoptosis.  
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Introduction 
One general characteristic of fast-growing solid 
tumors including breast cancer is the development of 
intratumoral hypoxia, whose existence correlates with 
a more malignant tumor phenotype and worse diag-
nosis. Adaptation to the hypoxic environment is crit-
ical for tumor cell survival and growth. The hypoxic 
cells in tumors modify gene expression in order to 
obtain a blood supply and prevent cellular damage; 
the main mediator of the hypoxia response is hypox-
ia-inducible factor-1 (HIF-1) (1). HIF-1 is a transcrip-
tional activator for a group of genes that are respon-
sible for promoting tumor cell angiogenesis and pro-
gression (1, 2). HIF-1 is composed of an inducible 
subunit, HIF-1α and a constitutively expressed sub-
unit, HIF-1ß (3). Under normal oxygen tension, 
HIF-1α is rapidly degraded by posttranslational ubi-
quitination-triggered proteolysis. However, under 
low oxygen tensions (hypoxia), HIF-1α becomes sta-
bilized. After nuclear translocation, HIF-1α hetero-
dimerize with HIF-1ß to form transcriptional activator 
HIF-1, which binds to HRE within the promoter re-
gions of target genes (such as VEGF) and thus regu-
lates gene transcription (4).  
  p16, a tumor suppressor gene and cyclin D ki-
nase inhibitor and a negative cell cycle regulator (5, 6), 
was shown to be able to inhibit breast cancer angi-
ogenesis and metastasis (7). While our previous stu-
dies showed that p16 downregulates VEGF gene ex-Journal of Cancer 2010, 1 
 
http://www.jcancer.org 
127
pression and neutralizes HIF-1α transactivation ac-
tivity, it is not known whether p16 directly affects one 
or more aspects of malignant progression such as 
adhesion and migration of breast cancer cells in order 
to suppress metastasis. Particularly, cell migration is 
an important aspect of the tumor metastatic process 
that transforms the tumor cells from local, noninva-
sive confined cells to the migrating, metastatic cancer 
cells. There are many reports showing hypoxia plays 
an important role in tumor angiogenesis and tumor 
progression, however, very few studies have been 
done to date with regard to analyzing how hypoxia 
specifically affects cell migration. Study on whether 
HIF-1α is involved in cell migration is rare: while 
there are reports implying that HIF-1α may stimulate 
tumor cell migration (8, 9), no substantial evidence is 
available at present; moreover, no study has been 
done on whether p16 can inhibit hypoxia-mediated 
cell migration. In this study, we evaluated whether 
hypoxia stimulate breast cancer migration and 
whether HIF-1α is involved in this process; in addi-
tion, we were particularly interested in determining 
whether p16, which was shown to neutralize the 
function of HIF-1α (6)--the master transcriptional fac-
tor in response to hypoxia, directly affects one or more 
aspects of the malignant process, particularly in the 
hypoxia–mediated cell migration, of breast cancer 
cells.  
Materials and methods 
Cell lines, cell culture conditions, and reagents 
Human breast cancer cell lines MDA-MB-231 
and mouse mammary carcinoma cell line 4T1 were 
obtained from American Type Culture  Collection 
(ATCC, Manassas, VA). Murine mammary carcinoma 
cell line JygMC(A) is a generous gift from Dr. H. 
Azuma of Osaka Medical College, Osaka, Japan (10). 
MDA-MB-231 cells and 4T1 cells were grown in 
RPM1-1640 (Gibco BRL, Gaithersburg, MD) with 10% 
fetal bovine serum (FBS) (Hyclone Laboratories, Lo-
gan, UT), JygMC(A) cells were grown in Dulbecco’s 
Modified Eagle medium (D-MEM) (Gibco BRL) with 
10% FBS. All cell lines were grown in medium con-
taining 100 units/ml penicillin, and 100 μg/ml strep-
tomycin. The cell cultures were incubated at 37°C 
either under nomorxia (5% CO2, 21% O2) or hypoxia 
(5% CO2, 1% O2, balanced with N2) conditions. 
Generation and screen of stably transfected, Dox 
inducible (Tet-on) p16-expressing breast cancer 
cell lines 
The construction of the Tet-on p16 lentiviral 
system Lenti-Tet-on p16 (pLenti-Tet-p16-pgkpuro and 
pcFUW-rtTA3-IRES-puro) was described previously 
(6). Breast cancer cells (MDA-MB-231, 4T1, and 
JygMC(A), respectively) were co-transduced by 
pLenti-Tet-p16-pgkpuro and pcFUW-rtTA3-IRES- 
puro at multiplicity of infection (moi) of 10 each, to-
gether with 6 μg/ml polybrene (Millipore, Bedford, 
MA). The stably transfected cells were enriched in 
medium containing 1 μg/ml puromycin (Clontech, 
Mountain View, CA). The resultant stably transfected 
cells are named as MDA/Tet-on p16, 4T1/Tet-on p16, 
and JygMC(A)/Tet-on p16, respectively. Similarly, 
breast cancer cells stably infected with lentiviral sys-
tem expressing green fluorescent protein (GFP) re-
porter gene under inducible Tet-on promoter (Len-
ti-Tet-on GFP) were generated. For induction of p16 
or GFP transgene expression, 1 μg/ml doxycyline 
(Dox) (Clontech) was used in the medium for incuba-
tion.  
Immunohistochemistry 
For  in vitro immunohistochemistry (IHC), the 
culture cells were grown on SlideFlasks with detach-
able bottom slides (Nalge Nunc, Naperville, IL) that 
c o u l d  b e  d i r e c t l y  u s e d  f o r  I H C  s t a i n i n g  l a t e r .  T h e  
samples (slides) were incubated with the first anti-
body against human p16 (mouse anti-human p16 an-
tibody, Santa Cruz Biotechnology, Inc., Santa Cruz, 
CA) for 16 h, then by a corresponding second anti-
body (goat anti-mouse antibody) and the Universal 
Elite ABC Kit (Vector Laboratories, Inc., Burlingame, 
CA) according to the manufacturer's protocol. The 
reaction was visualized with DAB solution (75 mg 
3,3’-Diaminobenzidine and 30 μl 50% H2O2 in 150 ml 
PBS) for 3-10 min. 
Growth proliferation assay 
  Briefly, the breast cancer cells were plated at 
5x104 cells per well in the 6-well culture plate and 
incubated at 37°C in the absence or presence of 1 
μg/ml Dox (for p16 induction). Cellular proliferation 
was measured by cell counting of the attached cells at 
day 5 after Dox treatment.  
Adhesion assay  
The breast cancer cells were incubated in the 
absence or presence of 1 μg/ml Dox for 72 h. The cells 
were then harvested and resuspended at 4x105 
cells/ml in 1% FBS-medium. The cell suspensions 
were rested at 37°C in a CO2 incubator for 30 min. A 
24-well tissue culture plate, which was precoated with 
matrigel matrix (BD Biosciences, Bedford, MA) by 
adding 250 µl of 10 µg/ml Matrigel per well for 2 
hours and followed by blocking with 5% BSA in PBS 
for 1 h at 37°C, were used to seed viable 8×104 cells (in 
200 µl cell suspension) in each precoated well of the Journal of Cancer 2010, 1 
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24-well plate and incubated for 4 h at 37°C. The non-
adherent cells were then removed by washing 4 times 
with PBS. Then, the adherent cells were fixed with 4% 
paraformaldhyde for 10 min and stained using 1% 
toluidine blue for 5 min. After extensive washing with 
water, cells attached to the plates were solubilized 
with 1% SDS. The absorbance at 560 nm was used to 
quantify the cells as cell adhesion ability.  
Transactivation assay of VEGF promoter 
The MDA/Tet-on p16 cells were incubated in 
medium containing with or without 1 μg/ml Dox for 
2 days prior to cotransfection. A chimeric construct 
containing a 2.4-kb VEGF promoter and a luciferase 
reporter gene (pVEGF/Luc) (a generous gift from Dr. 
BH Jiang of West Virginia University was cotrans-
fected at 10:1 ratio (w:w) with phRLuc-TK (Promega), 
a plasmid expressing Renilla luciferase as an internal 
control for normalization of transfection efficiency, by 
Fugene 6 (Roche, Indianapolis, IN) according to the 
manufacturer’s instruction. Forty-eight h after trans-
fection, the cell extracts were harvested and analyzed 
for luciferase activity using Dual-Luciferase Assay Kit 
(Promega) as instructed by the manufacturer’s in-
struction. The normalized luciferase activity was 
represented as ratio of Firefly luciferase activity 
(pVEGF/Luc) over Renilla luciferase activity 
(phRLuc-TK).  
To ensure the increased VEGF transactivation 
under hypoxia is indeed due to the increased activity 
of HIF-1α, a HIF-1α inhibitor YC-1 (Alexis Biochemi-
cals Corp., San Diego, CA) and two other chimeric 
luciferase reporter gene constructs, pMAP11WT and 
pMAP11mut (both generous gifts from Dr. B.H. Jiang 
of West Virginia University. Ref. 11) were used re-
spectively to replace pVEGF/Luc in a similar transac-
tivation assay. pMAP11WT is a minimal VEGF pro-
moter/Luc chimeric construct that contains only 47 
bp of VEGF 5-flanking sequence encompassing a 
HRE, the hypoxia response element where HIF-1α 
binds to (2, 8), and pMAP11mut is exactly the same as 
pMAP11WT except it contains a mutant HRE se-
quence so HIF-1α binding site is abolished (2, 8). The 
luciferase activity was normalized with protein con-
centration.  
Cell motility/migration assay 
  The breast cancer cells were incubated in the 
absence or presence of 1 μg/ml Dox for 72 h. The cells 
were then harvested and used for the following mi-
gration assay. The cell migration/motility was meas-
ured by a modified Boyden’s chamber method using 
BD Falcon Cell Culture Inserts incorporating polye-
thylene terephthalate (PET) track-etched membrane 
with a pore size of 8.0 μm (BD Bioscience, Belgium). 
The inserts were precoated on the undersurface (be-
tween upper and lower chambers) with 10 µg/ml 
fibronectin (Thermo Fisher Scientific) at 370C for 3 h. 
Above mentioned harvested cells in suspension of 
serum-free medium (SFM) with 1% BSA were incu-
bated at 37°C for 30 min under nomorxia (5% CO2, 
21% O2) or hypoxia (5% CO2, 1% O2, balanced with 
N2) conditions. Subsequently, cell suspensions were 
seeded into the upper chamber of an insert at a den-
sity of 10,000 cells per well, and 300 µl serum-free 
medium with 1% BSA was placed in the lower 
chamber to act as a chemoattractant in the 24-well cell 
culture plate. The cells were further incubated at 
normoxia and hypoxia (see above) at 37°C for 3 h. The 
inserts were then removed and nonmigrating cells 
remaining on the upper side of the filter were scraped 
off. The cells that had migrated to the lower surface of 
the insert were stained using Giemsa staining solution 
(Sigma, St. Louis, MO). After extensive washing with 
water, the migrated cells were counted in five differ-
ent fields under a microscope at x200 magnification. 
Migratory activity was expressed as the number of 
cells (that is, the sum of total cell numbers in five 
randomly selected fields of view) that migrated to the 
lower side of the filter.  
Results 
Tet-on inducible transgene system via lentiviral 
stable transfection in breast cancer cells 
 To better study the p16 effects on several aspects 
of tumor malignant progression, inducible p16 ex-
pression is desired in the breast cancer cells in order to 
compare the p16 effects on the same cells. We de-
signed an inducible gene expression system in lenti-
virus where the transgene was placed under the con-
trol of a Tet-on promoter; the resultant lentiviral vec-
tors would be used to stably transfect the breast can-
cer cells. To prove that this lentiviral vector works as 
an inducible transgene expression system in our 
hands, breast cancer cells were used to transduce with 
lentivirus expressing an inducible reporter gene GFP, 
the stably transfected cells were enriched by the se-
lective reagent puromycin. The cells were then incu-
bated with 1 µg/ml Dox to induce the Tet-on promo-
ter controlled transgene GFP expression. As shown in 
Fig. 1, both breast cancer cells 4T1 and JygMC(A) 
demonstrated a near 100% transduction rate in terms 
of transgene GFP expression (Fig. 1A and 1C, respec-
tively). These results indicated that the Tet-on induci-
ble system by lentiviral vectors was able to success-
fully induce the desired transgene expression in the 
breast cancer cells by 1 µg/ml Dox. Likewise, another Journal of Cancer 2010, 1 
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breast cancer cell line MDA-MB-231 stably transfected 
with lentivirus expressing an inducible human 
wild-type p16 gene under the control of the Tet-on 
promoter was generated (MDA/Tet-on p16). The 
MDA/Tet-on p16 cells showed a 100% p16 protein 
induction in the presence of 1 µg/ml Dox (Fig. 1F). 
Importantly, MDA/Tet-on p16 cells in the absence of 
inducer Dox did not express p16 protein (Fig. 1E), 
indicating that it is a truly tightly regulated Tet-on 
inducible system.  
 
Figure 1. Induction of transgene by doxycycline (Dox) in breast cancer cells stably transduced with a re-
troviral-mediated Tet-on system. 4T1 (A and B) and JygMC(A) (C and D) cells stably infected with Lenti-Tet-on GFP 
were treated with 1 μg/ml doxycycline (Dox, a tetracycline analogue) for 72 h (A-D). The cells were then observed under 
a fluorescent microscope for transgene GFP expression. The same image of the cells (4T1, A and B; JygMC(A), C and D, 
respectively) at both fluorescent (A and C) and light-contrast (B and D) images are shown. E and F. Immunohistochemcal 
(IHC) staining for p16 protein on MDA-MB-231 cells stably infected with Lenti-Tet-on p16 (MDA/Tet-on p16). MDA/Tet-on 
p16 cells were treated either without (E) or with (F) 1 μg/ml Dox for 72 h. The cells (E and F) were then IHC stained by 
primary anti-p16 antibody. The dark brown color indicates p16 protein (F). Journal of Cancer 2010, 1 
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Effect of the expression of p16 protein on breast 
cancer cell growth  
Tumor progression and metastasis include pri-
mary tumor growth, invasion through basement 
membrane and extracellular matrix, dissemination to 
lymphatic and/or blood circulation, migration to 
distant organs, and colonization at the secondary site 
(12). All these aspects of tumor progression contribute 
to the final net result of secondary tumor (metastasis) 
formation. Accordingly, several corresponding in vitro 
assays, including proliferation, adhesion, migration, 
in vitro invasion assays, can be applied to analyze the 
individual aspect of the tumor progression.  
To study the effect of the induced p16 protein 
expression on breast cancer cell growth, breast cancer 
cells MDA/Tet-on p16 were treated with or without 
Dox and followed by measuring cell proliferation 
after 5 days treatment. A significant reduction of cell 
growth (about 45.6% inhibition) was observed when 
p16 expression was induced (Fig. 2), indicating that 
p16 inhibits breast cancer cell proliferation. Similar 
results were also observed in other breast cancer cells. 
The concentration of 1 µg/ml Dox did not have an 
effect on cell proliferation as evidenced by either 
treatment with 1 µg/ml Dox in parental breast cancer 
cells or cells stably expressing Tet-on GFP (not 
shown).  
 
 
 
 
 
Figure 2. p16 inhibits breast cancer cell prolifera-
tion. The breast cancer cells MDA/Tet-on p16 were in-
cubated with or without 1 μg/ml Dox for 5 days and the cell 
numbers were counted. The results represent the data 
from at least two independent experiments, each per-
formed in triplicate.  
 
 
p16 has no apparent effect on breast cancer cell 
adhesion ability 
To determine whether p16 modulates cell adhe-
sion of breast cancer cells on extracellular matrix, the 
cell adhesion assays were preformed on MDA/Tet-on 
p16 and other breast cancer cells. To detect any po-
tential Dox effect at 1 μg/ml concentration on cell 
adhesion, MDA/Tet-on GFP was also included. 
MDA/Tet-on p16 and MDA/Tet-on GFP cells were 
incubated with or without 1 μg/ml Dox for 3 days, 
and the treated cells were then plated on 24-well 
plates precoated with 10 μg/ml matrigel matrix. After 
4 h incubation, nonadherent cells were washed off 
and the adherent cells were stained and read at OD570. 
As shown in Fig. 3A, similar adhesion abilities were 
exhibited in both MDA/Tet-on p16 and MDA/Tet-on 
GFP lines under either presence or absence of Dox 
induction (Fig. 3A), indicating that (A) 1 μg/ml Dox 
did not affect cell adhesion behavior and (B) the ex-
pression of p16 protein has no significant effect on cell 
adhesion ability. Similar results were observed in the 
4T1/Tet-on p16 and 4T1/Tet-on GFP (Fig. 3B). These 
combined results indicated that p16 did not affect 
breast cancer cell adhesion.  
p16 neutralizes HIF-1α transactivation activity  
Our previous study using ectopic expression 
revealed that HIF-1α increases VEGF gene transcrip-
tion whereas p16 downregulates it in MDA-MB-231 
cells; moreover, p16 neutralizes HIF-1α stimulated 
transactivation activity (6). Because endogenous 
HIF-1α can also be induced by hypoxia in 
MDA-MB-231 cells (7), we intended to investigate 
whether p16 can also neutralize hypoxia-induced 
HIF-1α transactivity; if so, we would further analyze 
whether p16 inhibits HIF-1α/hypoxia induced cell 
migration, an important aspect of malignant tumor 
progression.  
First, we used MDA/Tet-on p16 to cotransfect 
with a full-length VEGF promoter chimeric luciferase 
reporter gene construct, pVEGF/Luc (13) and 
phRLuc-TK, and cells were incubated either with or 
without Dox to induce p16 expression. The cell ex-
tracts were harvested later and analyzed by a 
Dual-Luciferase Assay Kit for examining whether p16 
attenuated HIF-1α transactivity in terms of VEGF 
promoter activity. As shown in Fig. 4, the 
p16-expressing cells (Dox+) had reduced luciferase 
activity compared to that of its p16-nonexpressing 
counterpart (Dox-) in both normoxia and hypoxia 
conditions, with more significant effect under the 
hypoxia. These results indicate that p16 expression 
can attenuate HIF-1α’s transactivation activity.  Journal of Cancer 2010, 1 
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Figure 3. p16 does not appear to affect breast cancer cell adhesion. The breast cancer cells MDA/Tet-on p16 (or 
MDA/p16) and MDA/Tet-on GFP (or MDA/GFP) (A) or 4T1/Tet-on p16 (or 4T1/p16) and 4T1/Tet-on GFP (or 4T1/GFP) 
(B) were incubated with or without 1 μg/ml Dox for 72 h. The cells were then harvested and used for adhesion assay as 
described in M & M section. The results represent the data from at least two independent experiments, each performed in 
triplicate. The differences between with and without Dox treatment groups, as well as between Tet-on p16 and Tet-on GFP 
groups are not significant (p>0.05).  
 
 
Figure 4. p16 inhibits HIF-1α transcriptional activity 
under both hypoxia and normoxia conditions. 
MDA/Tet-on p16 cells were treated with or without 1 
µg/ml Dox and cotransfected with pVEGF/Luc and 
phRLuc-TK. The Dual-Luciferase Assay Kit was used to 
analyze the luciferase activity of cell extracts. The norma-
lized luciferase activity was represented as ratio of Firefly 
luciferase activity (pVEGF/luc) over Renilla luciferase activ-
ity (phRLuc-TK). The results represent the data from three 
independent experiments, each performed in duplicate. 
Some error bars are too small to be seen in this scale. 
 Journal of Cancer 2010, 1 
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Binding of HIF-1α to the HRE is required for the 
hypoxia mediated HIF-1α transactivation 
To ensure the elevated transactivation ability in 
terms of VEGF promoter transactivation under hy-
poxia we observed above (Fig. 4) is mainly mediated 
by HIF-1α, a HIF-1α inhibitor agent YC-1 (14) was 
included in a similar assay. We observed a 
dose-dependent reduction of HIF-1α transactivation 
activity by YC-1 on pVEGF/Luc (not shown). To fur-
ther confirm/determine that result of our transactiva-
tion assay is indeed due to the HIF-1α binding that 
modulates VEGF promoter transactivation (the rea-
dout of HIF-1α transactivation), two minimal VEGF 
promoter chimeric luciferase reporter gene constructs, 
pMAP11WT (which contains only 47 bp of the VEGF 
5-flanking sequence encompassing a HRE where 
HIF-1α binds to); and pMAP11mut (which is the same 
as pMAP11WT except it contains a mutant HRE se-
quence so the HIF-1α binding site is abolished) (11) 
were also included in a similar study. As shown in 
Fig. 5, only pMAP11WT, not pMAP11mut, had an 
increased transactivation under hypoxia compared to 
that under normoxia; furthermore, while YC-1 exhi-
bited a dose-dependent reduction of HIF-1α mediated 
transactivation on pMAMP11WT under hypoxia 
(similar to that of the full-length VEGF promoter, not 
shown), YC-1 has no apparent effect on pMAP11mut 
(Fig. 5). These results clearly indicate that the binding 
of HIF-1α to the HRE is required for both hypox-
ia-induced transactivation and YC-1 mediated inhibi-
tion of VEGF promoter, implying that indeed HIF-1α 
is mainly responsible for the hypoxia induced trans-
activation of VEGF promoter and YC-1 mediated in-
hibition of this transactivation under hypoxia.  
Hypoxia increases cell migration in breast cancer 
cells 
  Cell migration is an important aspect of the tu-
mor metastatic process. HIF-1α was implied in sti-
mulation of cancer cell migration (8, 15) and hypoxia 
induces HIF-1α (7). Thus, we were interested in ana-
lyzing whether hypoxia has effect on breast cancer cell 
migration. First, we used 4T1/Tet-on GFP cells to 
study whether hypoxia induces cell migration and 
whether Dox per se had any effect on the cell migra-
tion. As shown in Fig. 6, hypoxia induced cell migra-
tion significantly, regardless the cells were incubated 
with or without Dox; on the other hand, 1 µg/ml Dox 
did not have any effect on cell migration, as evidenced 
by 4T1/Tet-on GFP with Dox, which did not show 
altered migration behavior compared to that of the 
cells without Dox treatment in both normoxia and 
hypoxia (Fig. 6). These results revealed: (A) hypoxia 
induced breast cancer cell migration; (B) Dox treat-
ment per se did not have any effect on cell migration 
(Fig. 6). 
 
 
Figure 5. Hypoxia induced VEGF promoter transactivation and its inhibition by YC-1 involve HRE, the 
HIF-1α binding region of the promoter. MDA-MB-231 cells were transfected with pMAP11WT and pMAP11mut, 
followed by either normoxic or hypoxic conditions, and luciferase activity analysis as described in M & M section. A serial 
concentration of YC-1, a HIF-1α inhibitor, was added in the medium of cell samples under hypoxia in order to inhibit the 
hypoxia-induced HIF-1α transactivation activity. The normalized data is presented. The results represent the data from at 
least two independent experiments, each performed in duplicate.  Journal of Cancer 2010, 1 
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Figure 6. Hypoxia increased cell migration/motility 
in breast cancer cells. The breast cancer cells 
4T1/Tet-on GFP cells were incubated with or without 1 
μg/ml Dox for 72 h, followed by 24 h in hypoxic or nor-
moxia incubation prior to be used for cell migration assay as 
described in M & M section. The results represent the data 
from at least two independent experiments, each per-
formed in triplicate.  
p16 inhibits hypoxia-mediated breast cancer 
migration 
  As we showed above, induced HIF-1α by hy-
poxia is responsible for the elevated VEGF transacti-
vation (Fig. 5) and p16 can neutralize this 
HIF-1α-mediated action (Fig. 4); we were interested in 
determining whether p16 modulates cell migration as 
well, particularly under hypoxia conditions which 
was shown to increase cell migration (Fig. 6). 
MDA/Tet-p16 cells were treated with (p16 induction) 
or without (no p16 expression) Dox for 3 days. The 
treated cells were seeded in the upper chamber of the 
transwell that has been precoated with 10 μg/ml fi-
bronectin at the undersurface. After 3 h at 37°C under 
either normoxia or hypoxia conditions, the cells that 
had migrated to the undersurface were counted. As 
shown in Fig. 7A, the cells under hypoxia had more 
than two fold increase in cell motility than that of 
normoxia (first two columns from the left, Fig. 7A); 
contrastingly, inducible p16 expression by Dox sig-
nificantly inhibited this hypoxia-induced cell migra-
tion (column 4, Fig. 7A), with an approximate 36.0% 
inhibition in comparison to cells under hypoxia 
without p16 expression (column 2, Fig. 7A). The mi-
gration of cells under normoxia were also inhibited by 
p16 expression (17.1% inhibition), although not as 
effective as that under hypoxia (compare column 1 
and column 3, Fig. 7A), indicating that p16 can inhibit 
cell migration at both normoxia and hypoxia, with 
significantly more effect on inhibition of hypox-
ia-induced cell migration. These data suggest that 
hypoxia increases (probably through elevated HIF-1α 
contribution to) MDA-MB-231 cell migration, and p16 
is able to inhibit this hypoxia elevated cell migration. 
A similar result was observed in another breast cancer 
cell line 4T1/Tet-p16 where the induced p16 expres-
sion had a 38.8% inhibition on cell migration under 
hypoxia (Fig. 7B). These results, taken together with 
Fig. 4, Fig. 5 and Fig. 6, imply that p16 may inhibit 
hypoxia/HIF-1α elevated cell migration by neutra-
lizing/attenuating the activity of HIF-1α induced by 
hypoxia.  
 
Figure 7. p16 inhibits hypoxia-induced cell migra-
tion. (A) The breast cancer cells MDA/Tet-on p16 cells 
were incubated with or without 1 μg/ml Dox for 72 h, 
followed by cell migration assay as described in M & M 
section in normoxic and hypoxic conditions. (B) 4T1/Tet-on 
p16 (or 4T1/p16) cells were incubated with or without 1 
μg/ml Dox for 72 h, followed by cell migration assay in 
hypoxic conditions. The results represent the data from at 
least two independent experiments, each performed in 
triplicate. 
 Journal of Cancer 2010, 1 
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Discussion 
In this report, we found that p16 inhibits breast 
cancer cell proliferation and migration, but has no 
apparent  effect on cell adhesion. Interestingly, p16 
shows much higher inhibition on cell migration in 
hypoxia than in normoxia. In addition, a parallel in-
hibition of HIF-1α  transactivation by p16 was ob-
served along with the p16-mediated inhibition of 
hypoxia-induced migration. As hypoxia promotes 
metastatic process and stimulates HIF-1α activation, 
these combined results imply a particular aspect of 
the metastatic process (such as migration) may be 
contributed, at least in part, by HIF-1α; and that p16 
can effectively inhibit that aspect by inactivating 
HIF-1α. Noticeably, this study is the first report to our 
knowledge demonstrating that p16 inhibits hypox-
ia-induced cell migration in breast cancer cells, in pa-
rallel with its inhibition of HIF-1a transactivation ac-
tivity. This study suggests that p16’s ability to sup-
press tumor metastasis may be partially resulted from 
p16’s inhibition on cell migration, in addition to its 
known functions on inhibition of cell proliferation, 
angiogenesis and induction of apoptosis.  
Cell migration plays a central role in a wide va-
riety of biological phenomena in both normal physi-
ology and pathophysiology. Particularly in a tumor 
setting, cell migration is the transition process from 
the local, confined tumor cells to metastatic cancer 
cells when the cells obtain the ability to dissociate 
from intracellular adhesions and become motile (16, 
17), which is usually driven by complex regulatory 
signaling cascades that transiently and/or perma-
nently alter the expression of a multitude of genes that 
act to reorganize the cytoskeletal network (17, 18). 
Several motility/migration related proteins have been 
implicated to play important roles in tumor metastatic 
process (19-24). A previous study showed that vitexin, 
a HIF-1α inhibitor, significantly inhibited migration of 
rat pheochromocytoma PC12 cells along with hypox-
ia-induced activation of c-Jun N-terminal kinase 
(JNK) (8). A more recent study revealed that hypoxia 
induced a cell migration in colorectal carcinoma cells 
and this increased migration was mediated by human 
enhancer of filamentation 1 (HEF 1), a 
HIF-1a-regulated gene (9). These reports suggest that 
hypoxia or HIF-1α may play a role in cancer cell mi-
gration. Consistently, our results indicated that hy-
poxia increases breast cancer cell migration (Fig. 6), 
and p16 significantly inhibits hypoxia-induced 
MDA-MB-231 and 4T1 cell migration (Fig. 7A and 7B).  
  Previous studies demonstrated that binding of 
HIF-1α to the HRE requires wild-type HRE and mu-
tation in this sequence would abolish such binding (2, 
8). By using a pair of minimal VEGF promoter chi-
meric reporter constructs, one contained with 
(pMAp11WT) and one without (pMAP11mut) 
“HIF-1α-binding capable” HRE, we confirmed the 
requirement of HIF-1α binding to the VEGF promoter 
(i.e., the presence of HRE) for HIF-1α mediated 
transactivation (Fig. 5). The parallel inhibition of 
HIF-1α transactivation (Fig. 4) and hypoxia-induced 
cell migration by p16 (Fig. 7), together with the fact 
that p16 neutralizes HIF-1α function and hypoxia 
induces HIF-1α activation (see above), implies that 
p16 may inhibit cell migration in breast cancer cells by 
neutralizing HIF-1α mediated cell migration stimu-
lated by hypoxia. To further verify whether this hy-
poxia-induced increased cell migration requires 
HIF-1α (Fig. 2A) and whether this p16-mediated in-
hibition of cell migration is truly due to the p16’s 
neutralization of HIF-1α’s transactivation function, 
we will examine p16 effects on the migration ability in 
a HIF-1α k n o c k o u t  b r e a s t  c a n c e r  c e l l s  b o t h  i n  n o r -
moxia and hypoxia (work in process). Our ongoing 
study showed that hypoxia stimulated breast cancer 
cell migration in HIF-1α wild-type breast cancer cells 
but not in their HIF-1α knockout counterparts, im-
plying hypoxia induced elevated cell migration re-
quires HIF-1α (our unpublished results). In addition, 
we are also in the process of determining whether p16 
has effects on breast cancer cells’ invasion abilities, 
another aspect of tumor progression, by the in vitro 
invasion assay. 
The development of intratumoral hypoxia is a 
common characteristic for fast-growing solid tumors 
including breast cancer. The main mediator of cells 
responding to hypoxia is activation of HIF-1, the 
master transcriptional factor which stimulates a group 
of downstream genes including VEGF that are re-
sponsible for tumor malignant progression (2, 25). 
HIF-1α is the inducible and regulatory subunit of the 
HIF-1; therefore, targeting and inhibiting the activity 
of HIF-1α should provide a therapeutic strategy to 
effectively block its regulated downstream signaling 
pathway and consequently suppress breast cancer 
malignant progression and metastasis. p16 is a bio-
logical agent that can inhibit/neutralize 
HIF-1α-mediated action on several levels of tumor 
progression, including growth, migration, angioge-
nesis which all contribute to the metastatic cascade. 
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